newsfilter
← Latest News
Business Wire·

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and